8-K: Annovis Bio Announces Positive Clinical Trial Results and Second Quarter Financials

Annovis Bio reported encouraging clinical trial results for its drug buntanetap in Alzheimer's and Parkinson's disease, along with its second quarter 2024 financial results.

Summary

• Annovis Bio announced its second quarter financial results and provided a business update.
• The company completed Phase 2/3 Alzheimer's and Phase 3 Parkinson's studies, both showing positive data for buntanetap.
• A new crystalline form of buntanetap with improved properties was introduced, strengthening the company's IP portfolio.
• The Phase 2/3 Alzheimer's study showed a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment with buntanetap, compared to a 0.3-point improvement in the placebo group.
• A follow-up analysis showed a 3.15-point improvement in cognition among high-risk APOE4 carriers.
• The Phase 3 Parkinson's study revealed significant improvements in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and cognition.
• Buntanetap halted cognitive decline in all enrolled Parkinson's patients and improved cognition in those with mild dementia.
• Annovis Bio received $7.1 million net cash from exercises of Canaccord warrants in July 2024 and $7.0 million net cash from the ELOC facility announced in April 2024.
• The company's cash and cash equivalents totaled $4.0 million as of June 30, 2024, and increased to $12.1 million as of August 14, 2024.
• Total operating expenses for the three months ended June 30, 2024, were $7.8 million, including $5.8 million in research and development expenses.
• The company reported a $0.44 basic and diluted net loss per common share for the three months ended June 30, 2024.
• A new composition of matter patent was filed covering a novel crystal form of buntanetap, offering better solubility and stability and an additional 20 years of patent life.
• The company received FDA approval to continue phase 3 development with the new crystal form on July 16, 2024.
• Annovis Bio expanded its team with several key appointments, including a Chief Business Officer, Director of Strategic Communications, Senior Vice President of Statistics, and Head of Quality.
• New preclinical data showed a synergistic improvement on cognition when combining buntanetap with the GLP-1 agonist Trulicity.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, a new patent, and a strengthened financial position, indicating a strong positive sentiment.

Positives

• Clinical trials for buntanetap in both Alzheimer's and Parkinson's disease showed significant positive results.
• The new crystalline form of buntanetap has improved properties and extends patent life.
• The company has secured additional funding through warrant exercises and an ELOC facility.
• The company has expanded its team with key appointments.
• Preclinical data suggests a synergistic effect when combining buntanetap with Trulicity.

Negatives

• The company reported a net loss of $0.44 per common share for the three months ended June 30, 2024.
• The company's cash and cash equivalents were $4.0 million as of June 30, 2024, which is relatively low before the recent capital raise.

Risks

• The company's future success depends on the effectiveness of buntanetap in clinical trials.
• There are risks associated with patient enrollment and the timing of clinical trials.
• The company's financial position is dependent on continued funding.

Future Outlook

The company believes its current cash position is sufficient to support operations through planned FDA meetings in the Fall and until the initiation of two pivotal studies.

Management Comments

• The recent months have been productive for our company, said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio.
• We've completed pivotal Phase 2/3 Alzheimer's and Phase 3 Parkinson's studies, both of which revealed very encouraging data for buntanetap.
• Additionally, we've introduced a new crystalline form of buntanetap with improved properties, further strengthening our IP portfolio.
• These milestones position us strongly as we move closer to providing much-needed treatments to patients.

Industry Context

The positive results from Annovis Bio's clinical trials are significant in the context of the ongoing search for effective treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, which have a high unmet medical need. The development of a new crystalline form of buntanetap also highlights the importance of innovation in drug development.

Comparison to Industry Standards

• The 3.3-point improvement on the ADAS-Cog11 test in the Annovis Bio study is a notable result when compared to other Alzheimer's drug trials, where improvements are often smaller or not statistically significant.
• For example, some trials of other amyloid-targeting drugs have shown cognitive improvements of around 1-2 points on the ADAS-Cog scale, making Annovis's results appear promising.
• The halt of cognitive decline in all enrolled Parkinson's patients and improvement in those with mild dementia is also a significant finding, as many current treatments only manage symptoms and do not slow disease progression.
• The development of a new crystalline form of buntanetap with improved properties is also a positive development, as it could lead to a more stable and effective drug product, which is a common challenge in pharmaceutical development.

Management Changes

Stakeholder Impact

• Shareholders are likely to react positively to the clinical trial results and the company's strengthened financial position.
• Employees may be encouraged by the company's progress and expansion.
• Patients with Alzheimer's and Parkinson's disease may have increased hope for new treatment options.
• The company's suppliers and creditors may view the company as a more stable and reliable partner.

Next Steps

• The company plans to have FDA meetings in the Fall.
• The company plans to initiate two pivotal studies.

Key Dates

Keywords

buntanetap, Alzheimer's disease, Parkinson's disease, clinical trials, neurodegenerative diseases, cognitive improvement, patent, financial results, FDA approval, APOE4, MDS-UPDRS, Trulicity